Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Berger

Diagnostic Radiology Annapolis, MD Medical Doctor

NPI 1841248515 CMS profile 310856

122 Defense Hwy, Chesapeake Medical Imaging, Annapolis, MD 21401

Open in the dashboard

General payments

$47,319

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Berger of Annapolis, MD is reported in the CMS Open Payments database as having received $47,319 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,898 15
2024 General $25,548 40
2023 General $705 10
2022 General $4,420 16
2021 General $1,933 14
2020 General $259 6
2019 General $556 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Berger
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Kevin Berger were reported at $13,898. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Kevin Berger Diagnostic Radiology median Middle half National median
2019 $556 $108 $29–$318 $163
2020 $259 $65 $21–$252 $114
2021 $1,933 $92 $24–$292 $132
2022 $4,420 $104 $29–$294 $149
2023 $705 $110 $29–$337 $160
2024 $25,548 $113 $30–$356 $164
2025 $13,898 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Blue Earth Diagnostics Limited $22,066 35 payments
  2. Canon Medical Systems USA, Inc. $19,781 32 payments
  3. Curium US LLC $3,624 2 payments
  4. Piramal Imaging Limited $581 11 payments
  5. Ge Healthcare $367 8 payments
  6. Telix Pharmaceuticals $271 3 payments
  7. Biogen, Inc. $184 8 payments
  8. Horizon Therapeutics plc $128 2 payments
  9. Progenics Pharmaceuticals, Inc. $117 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $84 1 payment
  11. Other $116 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $20,250 7 payments
  2. Consulting Fee $18,820 6 payments
  3. Food and Beverage $4,930 78 payments
  4. Travel and Lodging $3,261 15 payments
  5. Education $58 1 payment
Products named General payments · program years 2019–2025
  1. POSLUMA $20,386 32 payments
  2. Vantage Galan 3T $4,769 4 payments
  3. TOSHIBA SUPERCONDUCTING MRI SYSTEM Vantage Titan $4,080 1 payment
  4. PET-CT SCANNER $4,000 2 payments
  5. Canon PET/CT Scanner $2,774 4 payments
  6. TOSHIBA SCANNER $2,500 1 payment
  7. Axumin $1,680 3 payments
  8. NEURACEQ $581 11 payments
  9. GENERAL DEVICE(S) $402 6 payments
  10. ILLUCCIX $271 3 payments
  11. Other $1,481 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$2,330,676

Of which drugs: $6,654

Medicare patients

2,653

Average age 75

Services billed

76,198

1,551 women, 1,102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 33%
Depression 27%
Ischemic heart disease 26%
Alzheimer's or dementia 25%
Chronic kidney disease 22%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 397 54,916 $5,162
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 114 12,009 $1,237
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 73 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
POSLUMA
  • Blue Earth Diagnostics Limited $13,713
$13,713 — —
NEURACEQ
  • Piramal Imaging Limited $210
$210 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record